Background: The Wnt/beta-catenin and the Hedgehog (Hh) pathway interact in various cell types while eliciting opposing or synergistic cellular effects. Both pathways are known as exclusive drivers of two distinct molecular subtypes of medulloblastoma (MB). In sonic hedgehog (Shh)-driven MB, activation of Wnt signaling has been shown to suppress tumor growth by either beta-catenin-dependent or -independent inhibition of Shh signaling. However, mechanistic insight in how beta-catenin inhibits the Hh pathway is not known. Findings: Here we show that beta-catenin stabilization by the glycogen synthase kinase 3 inhibitor lithium chloride (LiCl) reduced growth of primary hedgehog-driven MB tumor spheres from patched heterozygous mice (Ptch +/-) in vitro. LiCl treatment of MB spheres down-regulated the Hh target Gli1, whereas the repressive Gli3 protein (Gli3R) was increased. Mechanistically, we show by co-immunoprecipitation and proximity ligation assay that stabilized beta-catenin physically interacts with Gli1, leading to Gli1 sequestration and inhibition of its transcriptional activity. Reduction of Hh signaling upon LiCl stimulation resulted in reduced proliferation, sphere self renewal, a G2/M arrest and induction of a senescent-like state, indicated by p21 upregulation and by increased staining of senescence-associated beta-galactosidase (SA-betaGal). Moreover, LiCl treatment of subcutaneously transplanted MB cells significantly reduced tumor initiation defined as "tumor take". Although tumor progression was similar, LiCl-treated tumors showed decreased mitotic figures and phospho-histone H3 staining. Conclusion: We propose that beta-catenin stabilization increases its physical interaction with Gli1, leading to Gli1 degradation and inhibition of Hh signaling, thereby promoting tumor cell senescence and suppression of "tumor take" in mice.
Introduction
In medulloblastoma (MB), the most common malignant pediatric brain tumor, Wnt pathway-driven tumors represent one of four distinct molecular subgroups with particularly favorable prognosis [1] [2] [3] [4] . MB of the sonic hedgehog (Shh) subgroup account for up to 25-30% of human MBs and carry frequently mutations in the Shh receptor patched 1 (ptch1) [2, [5] [6] [7] . The prognosis of Hh-driven MBs is less favorable then the one of Wnt-driven MB and despite current multimodality treatment, MB patients suffer from considerable treatment-induced side effects [8, 9] .
In the "canonical" Wnt pathway β-catenin acts as a transcription factor with members of the lymphoid enhancer factor (Lef )/T-cell factor family [10] . On Wnt ligand-mediated activation of a complex formed by frizzled receptors and low-density lipoprotein receptor-related protein 5/6, proteasomal degradation of β-catenin is inhibited by inactivating the destruction complex formed by glycogen synthase kinase 3 β (GSK-3β), adenomatous poliposis coli (APC), and axin. Hedgehog, and specifically Shh, functions as a mitogen driving proliferation of granule neuron precursors in the cerebellum [11] . In the absence of Shh, patched (Ptch), a 12-transmembrane spanning protein, represses smoothened (SMO) thereby inhibiting Hh signaling. SMO is a member of the 7-transmembrane spanning G-protein-coupled receptor-like superfamily. On Shh binding to Ptch its repressive function on SMO is released, thereby activating Gli1/2 dependent transcription. In the repressive state Gli1/2 proteins are phosphorylated, ubiquitinated and degraded [12] .
Interestingly, Wnt and Shh were shown to interact in various cell types and organs during development and in the adult, while eliciting opposing or synergistic cellular effects. Generally, it has previously been shown that Shh inhibits the Wnt pathway during tongue papilla development and in squamous cell carcinoma [1, 3, 4, 13, 14] .
Recently, also in MB interaction of the Wnt and Hh pathway has been shown, describing either a β-catenindependent or -independent inhibition of Shh signaling by Wnt [5, 6, 15] .
However, neither mechanistic insight into β-cateninmediated inhibition of the Hh pathway, nor the therapeutic potential of Wnt/β-catenin-activating drugs has been examined specifically in MB. Here we show that the FDA-approved drug LiCl, which results in β-catenin stabilization via GSK-3 inhibition, suppressed formation of Ptch +/-MB tumor spheres as well as tumor take in mice. We provide mechanistic evidence that this effect is dependent on the physical interaction of Gli1 and β-catenin, leading to Gli1 degradation, G2/M cell cycle arrest and cellular senescence.
Findings
Primary MB cells isolated from Ptch +/mice [8] were treated with 10 mM LiCl in vitro. Inhibition of GSK-3 by LiCl, evidenced by GSK-3 phosphorylation (Figure 1a ), led to reduced tumor sphere self-renewal (Additional file 1: Figure S1a ) as well as to reduced tumor cell growth (Additional file 1: Figure S1b ). In accordance, β-catenin stabilization and transcriptional activation, confirmed by increased Axin2 mRNA ( Figure 1b ) and protein levels (Additional file 2: Figure S2 ), led to the downregulation of the Hh targets Gli1, Ptch1 and Hhip, on the mRNA level evidenced by qRT-PCR (see Table 1 for primer list), suggesting an inhibitory effect of β-catenin on Hh-induced transcription (Figure 1b ). The decrease of Gli1 as well as an increase in β-catenin protein stability was verified by treatment with (2'Z,3'E)-6-Bromoindirubin-3'-oxime (6BIO), a non-FDA-approved but highly specific inhibitor of GSK-3 (Additional file 3: Figure S3 ) [16] .
As shown in the developing spinal cord, activated Wnt/ β-catenin signaling increases the expression of repressive Gli3 (Gli3R), which in turn inhibits the Hh pathway [4, 11] . We corroborated Gli3R up-regulation upon LiCl treatment in Ptch +/-MB spheres on the protein level ( Figures 1c, d, e ). However, we cannot judge on the direct regulation of Gli3R via β-catenin. It should be noted that a ternary complex between Gli3R/α-catenin/β-catenin has been observed in chondrocytes, leading to the inhibition of β-catenin transcriptional activity [2, 7, 17] . In the Ptch +/-MB tumor spheres, we were not able to detect such a complex by co-immunoprecipitation at 8 h of LiCl treatment (data not shown).
Although the up-regulation of Gli3R and the concomitant down-regulation of Ptch1, Hhip and Gli1 either on mRNA or protein level fit to the interpretation of Hh pathway inhibition by LiCl-mediated β-catenin stabilization, the mechanism of Gli1 down-regulation remained elusive. To evaluate if proteasomal degradation diminishes Gli1 we investigated the effect on Gli1 protein by the proteasome inhibitor MG-132. LiCl-mediated decrease of Gli1 was partly reversed by proteasomal inhibition (Figures 2a, b ). However, the exact mechanism of Gli1 degradation upon β-catenin stabilization requires further investigation.
Furthermore, LiCl treatment significantly decreased cell proliferation, indicated by diminished Ki67-positive cells ( Figure 3a ) and by decreased cells marked by the more specific mitotic marker phospho-histone H3 (pHH3; Figure 3b ). Hence, LiCl treatment led to an accumulation of cells in G2/M cell cycle phase (Figures 3c, d ). As shown recently, G2/M accumulation also occurs in LiCl-treated endometrial and glioma cancer cell lines [13, 14] , and LiCl treatment of pancreatic ductal adenocarcinomas reduces the tumorigenicity of cells through Hh inhibition [15] .
Along this line, here we show that in primary Ptch +/-MB cells LiCl treatment increased the number of senescence-associated β-galactosidase (SA-βGal)-positive cells ( Figure 3e ) and upregulated p21 after 72 h as a senescence marker (Figure 3f ). These findings suggest that LiCl induces a senescent-like state in MB tumor cells. Apoptosis however, was not detectable after 8 h, 24 h and 72 h of LiCl treatment investigated by annexin V staining (data not shown). Furthermore, LiCl treatment did not specifically increase autophagy in Ptch +/-MB spheres, evidenced by staining for LC3 (data not shown). However this aspect requires further investigation.
We next analyzed the downstream effects of GSK3 inhibition with respect to Wnt/β-catenin and Hh crosstalk, as β-catenin interaction with Gli1 has previously been suggested to occur in endometrial carcinoma in which both factors cooperate to drive tumor growth [18] . To this end we immunoprecipitated β-catenin from Ptch +/-MB cultures after 8 h LiCl stimulation and blotted for Gli1, which was significantly increased upon β-catenin stabilization by LiCl, although low amounts of co-precipitation was also detectable in the NaCl controls ( Figure 4a ). This suggests that stabilized β-catenin is able to sequester Gli1, making Gli1 unavailable for transcriptional activity and likely subjecting it to protein degradation.
To visualize the β-catenin-Gli1 interaction upon LiCl stimulation, we performed a proximity ligation assay (PLA) with antibodies against β-catenin and Gli1. Indeed, this approach corroborated the β-catenin-Gli1 Table 1 for primers). Axin2 served as a control for β-catenin transcription. Dashed line represents NaCl control (n = 6, p values left to right: *0.0150, *0.0046; Unpaired student's t-test in GraphPad Prism 5.01).
interaction observed in co-precipitation experiments (Figures 4b, c , Additional file 4: Figure S4 ). Furthermore, 3D reconstruction of confocal Z-stacks revealed the localization of a small fraction of β-catenin-Gli1 within the nucleus, whereas most of the complex localized to the cytoplasm of Ptch +/-MB tumor cells ( Figure 4b ). This observation suggests that β-catenin might sequester Gli1 in the nucleus as well as in the cytoplasm, thus inhibiting Gli1-mediated transcription. As published previously in tongue taste papilla turnover, in squamous cell carcinoma and in gastric cancer, the Hh pathway can equally inhibit β-catenin transcriptional activity [4, 19] .
Taking advantage of the putative mutual inhibition of Gli1 and β-catenin and to further analyze the specific role of Gli1 for functional interaction with β-catenin, we explored the inhibitory function of Shh on β-catenin signaling using WT as well as Gli1 -/mouse embryonic fibroblasts (MEFs). MEFs were transfected with the chimeric construct LEFΔN-βCTA, conferring dominant β-catenin-LEF transcription, and subsequently stimulated with control or Shh-conditioned medium (ShhCM) [20] . As a read-out we utilized the superTOP/FOP-FLASH assay, measuring luciferase activity driven by a LEF-responsive promotor [21] . Interestingly, the inhibitory function of ShhCM on β-catenin transcription was completely abrogated in Gli1 -/-MEFs (Figure 4d ), suggesting that the interaction of Gli1 with LEFΔN-βCTA is required for transcriptional inhibition. As the LEFΔN-βCTA construct contains only the C-terminal transactivation domain of β-catenin (amino acid 695-781), these findings are suggestive that the C-terminus of β-catenin is crucial for the interaction with Gli1. It will be interesting to analyze in detail which exact binding-domains of β-catenin and Gli1 are required for protein-protein interaction. Furthermore, we investigated the role of β-catenin for hedgehog-mediated MB sphere growth by knocking down β-catenin by a siRNA approach. Interestingly, knock-down of β-catenin abrogated the growth inhibitory function of LiCl treatment (Additional file 5: Figure S5 ). Together these findings suggest that β-catenin stabilization and availability is crucial for LiCl-induced Hh pathway inhibition via the sequestration of Gli1.
Finally, in order to understand if β-catenin activation might be beneficial for MB patients, we transplanted primary mouse Ptch +/-MB cells subcutaneously into the flanks of NMRI/nude mice and treated the animals with either LiCl (7,5 μl/g body weight, 1.2 M) or NaCl (7,5 μl/g body weight, 1.2 M) as control [9, 22] .
LiCl treatment resulted in a significant delay in initial tumor incidence that we defined as "tumor take", ranging between day 22 and 26 (Figure 5b) . Nevertheless, nearly all animals, irrespective of the treatment, developed tumors by day 32, with a tendency of smaller tumors in the LiCl group (Figures 5a, b) . Taking together this finding suggests that LiCl treatment significantly inhibits tumor take ( Figure 5b ), although we did not observe a significantly reduced tumor burden at the experimental endpoint.
However, we observed reduced mitotic figures in LiCl-treated tumors, which was supported by decreased phospho-histone H3 (pHH3)-positive cells (Figures 5c, d) . Figure 5 LiCl treatment delayed growth and decreased volume of Ptch +/-MB-derived tumors. (a) 1×10 6 cells in 100 μl PBS were subcutaneously injected into HsdCpb:NMRI-Foxn1nu mice (6-8weeks, Harlan Laboratories) and animals were treated with LiCl (7,5 μl/g body weight, 1.2 M) or NaCl (7,5 μl/ g body weight, 1.2 M) from day 5 post-transplantation. From day 21 tumors were measured daily thereafter (electronic disk micrometers, Vogel Germany), the mean of tumor volume was determined by the formula: π/6× maximal-diameter x minimal-diameter 2 (mm 3 ) until animals were sacrificed by day 32.
(b) Dots represent the percentage of tumor-bearing animals. Statics were performed using PSPP 0.8.2 as described previously [23] . Equal numbers (n = 7) from NaCl-or LiCl-treated mice were tested for tumor formation probability by a non-parametric one-tailed binomial proportions test, setting the expected outcome for tumor formation to 90%. There was no significant difference between the expectation and the tumor incidence for the NaCl- This reflects a reduced population of cells in M phase and suggests that the majority of cells are arrested in G2 phase, corroborating our in vitro findings (Figure 3b ). Apoptosis was not altered in LiCl-treated MB tumors, evidenced by cleaved caspase 3 staining (Additional file 6: Figures S6 a, b) . It is interesting however, that LiCl tumors showed decreased necrotic areas (data not shown), although tumor size did not significantly differ from controls. In this regard it is worth mentioning that we recently reported on a normalizing effect of β-catenin activation in endothelial cells of glioma vasculature [24] . This would support the hypothesis that LiCl treatment of subcutaneous MB tumors might affect both, cell proliferation as well as tumor microenvironment by normalizing the vasculature. When we analyzed MB tumors for vessel density and smooth muscle cell coverage by CD31 and αSMA staining, respectively, we did not observe significant differences between the NaCl-and the LiCl-treated group (Additional file 6: Figure  S6 c, d) . This result might be explained by the different tumor models used in the study of Reis et al. and the present manuscript. Glioblastoma are well known to be highly angiogenic, whereas MB does not strongly induce vessel growth [25] . This requires more in depth evaluation, also at different stages of tumor growth that is however beyond the scope of this study.
The overall tumor histopathology of the subcutaneous Ptch +/tumors did not differ with respect to extracellular matrix and GFAP staining (Additional file 7: Figure S7) .
The systemic treatment with LiCl and the resulting stabilization of β-catenin will always target more cell types then the tumor cell itself. Consequently, we have to estimate the benefit of the treatment by the net outcome of tumor burden. It should be noted that the clinical impact of these findings might relate to some types of Shh-driven MB that occur in infants and young adults, which are difficult to treat with established regimes or by Smo inhibitors that are currently in clinical trials [26] . It seems to be common to these treatment-resistant MBs that they carry mutations downstream of Ptch or Smo in genes such as suppressor of fused (SuFu) or Gli2. Herein the stabilization of β-catenin at an early time point of the disease might have beneficial effects by directly targeting Gli1 and by supporting the chemotherapeutic treatment of the tumor cells. It should be noted that it is likely that human Shhdriven MB, harboring a mutation in Ptch, also respond to β-catenin activation with reduction of Gli1. However, more work is required to evaluate the translational potential of our finding.
In summary our data show for the first time that activation of Wnt/β-catenin signaling by LiCl treatment inhibits proliferation of Shh-driven mouse MB via the interaction of β-catenin and Gli1.
This supports the concept that Gli1 interacts with β-catenin by default, and that an increase of stabilized β-catenin is able to sequester an increased amount of Gli1 and vice versa. This scheme of a balanced interaction implies that β-catenin stabilization could be titrated to a level at which virtually all Gli1 becomes sequestered, without affecting canonical Wnt pathway activation.
These findings may open novel possibilities for therapeutic interventions for MB patients.
Additional files
Additional file 1: Figure S1 . LiCl treatment reduced tumor cell selfrenewal and growth. (a) Ptch +/-MB cells were cultivated for one week with either 10 mM NaCl or LiCl, growth factors and NaCl/LiCl were added every third day. After 7 days tumor spheres were counted, dissociated mechanically and subsequently seeded for a second and third sphere forming clonal assay (CA1 -3). Ptch +/-MB cells were kept on either NaCl or LiCl to investigate if Ptch +/-MB cells might adapt to the LiCl treatment. p-Values left to right: **0.0020, ***0.0006, *0.0104. Ptch +/-MB cells seeded for three subsequent clonal assays (CA) showed no adaption to the LiCl treatment. Additional file 3: Figure S3 . β-Catenin stabilization by 6BIO treatment decreased Gli1 protein level and pHH3 positive cells. (a) Primary Ptch +/-MB spheres were treated with 10 μM 6BIO or DMSO as control, harvested after 72 h and lysed and separated in cytoplasmic (C) and nuclear fraction (N). Membranes were probed with antibodies against Gli1 (R&D Systems) and β-catenin (BD Transduction Laboratories). Lamin B1 (Abcam) and α-tubulin (Sigma-Aldrich) served as loading controls. Gli1 protein levels decreased, β-catenin protein levels increased under 6BIO treatment. (b) Primary Ptch +/-MB cells were seeded on μ-Slide 8 well ibi-Treat slides (ibidi, Martinsried, Germany) (8x10 4 cells/well) and treated with 10 μM 6BIO or DMSO as control. Immunocytochemistry was performed with rabbit-anti-pHH3 (Ser10) antibody (Merck Millipore) followed by Alexa-Fluor-56 goat-anti-rabbit antibody (life technologies) and DAPI. pHH3-positive cells were counted at a confocal microscope (Nikon Eclipse C1si; 40×, NA 1.3; oil immersion and normalized to total cell count. Bars represent mean ± s.d., (n = 3, p-value *** < 0.0001). Scale bar represents 50 μm. The number of pHH3 positive cells decreased under treatment with 6BIO.
Additional file 4: Figure S4 . Increased interaction of β-Catenin with Gli1 upon LiCl stimulation. For PLA, primary Ptch +/-MB cells were seeded on μ-slides (ibidi, Martinsried, Germany) and treated with NaCl or LiCl for 8 h. Cells were incubated with antibodies against Gli1 (R&D Systems) and β-catenin (BD Transduction Laboratories) and corresponding anti-goat (minus) or anti-mouse (plus) PLA probes. Ligation-mix, consisting of two oligonucleotides, and amplification-mix, consisting of nucleotides and fluorescently labeled oligonucleotides, was added (Duolink In Situ, Detection Kit orange (Excitation: 554 nm, Emission: 579 nm, Sigma-Aldrich). Samples were examined by confocal microscopy (Nikon Eclipse C1si; 40×/ 60×, NA 1.3/1.4; oil immersion; 50 pictures/condition).
Additional file 5: Figure S5 . β-catenin knock down with siRNA abrogated the growth inhibitory function of LiCl treatment. Primary Ptch +/cells were transfected with either 5nM or 10nM of Silencer®Select Pre-designed siRNA against β-catenin or a control#1 siRNA (Ambion, life technologies), MetafectenePro was used as transfection reagent and incubated for 5 h. (a) 24 h post transfection cells (5nM and 10nM) were treated with either NaCl
